About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Association Between Immune Checkpoint Inhibitors and the Hazard of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer Included in the French Real-Life ESME Cohort.

Researchers

Elisabeth Gaye, Clémence Leguillette, Léa Sinoquet, Marie-Cécile Le Deley, Stéphane Pouderoux, Frédéric Bigot, Victoria Ferrari, Nicolas Girard, Christos Chouaid, Didier Debieuvre, Yannick Le Guen, Jordi Remon-Masip, Grégoire Justeau, Clarisse Audigier Valette, Sophie Schneider, Olivier Bylicki, Thomas Filleron, Anne Madroszyk, Charles Dayen, Lionel Falchero, Pascale Dubray-Longeras, Courèche Kaderbhaï, Chrystèle Locher, Maurice Pérol, Anne-Laure Martin, Xavier Quantin, David Pasquier

Abstract

Immune checkpoint inhibitors (ICI) have dramatically changed the outcome of patients with non-small cell lung cancer (NSCLC) across all stages of the disease. Herein, we investigated the association between ICI as part of the first treatment (ICI-1) and the risk of onset of central nervous system (CNS) metastases (brain or leptomeningeal disease) in patients with advanced NSCLC (aNSCLC). We conducted a retrospective analysis of the real-world French Epidemiological Strategy and Medical Economics (ESME) cohort. We included all patients aged ≥ 18 years with aNSCLC and without CNS metastases at diagnosis, who started systemic treatment and/or radiotherapy between 2015 and 2020. We estimated the incidence of CNS metastases considering death and second cancer as competing events. We used cause-specific Cox models to evaluate the factors associated with the cause-specific hazard of CNS metastases, particularly the association between ICI-1 and the hazard of CNS metastases. Among 10,618 patients, 68.6% were male and 31.4% were female, 12.2% received ICI-1, with proportion increasing over time (4.3%  < 2017 versus 19.4% ≥ 2017, p < 0.001). Overall, the 5-year cumulative incidence of CNS metastases was 22.4% (95% CI 21.5-23.4%). In multivariable analysis, patients who received ICI-1 had a significantly lower cause-specific hazard of CNS metastases (cause-specific hazard ratio 0.60, 95% CI 0.51-0.71, p < 0.001), with stable results with the propensity score approach. A higher age, squamous NSCLC, and BRAF mutation were significantly associated with a reduced cause-specific hazard of CNS metastases. Conversely, the presence of non-CNS metastases and EGFR, KRAS, or STK11 mutations were significantly associated with a higher hazard of CNS metastases. On the basis of this real-world retrospective study, patients with aNSCLC appear to have a lower hazard of CNS metastases when treated with ICI-1.
Source: PubMed (PMID: 43050112)View Original on PubMed